LPCAT3

Across TCGA pan-cancer cohorts, LPCAT3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LPCAT3 data layer compared with 18 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LPCAT3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LPCAT3 expression acts as an unfavorable survival marker, although some lineages such as OV and LSCC show a favorable association.

CCRCC, OV, and LUAD are the cancer types where LPCAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	22	view →
OV	DFS	Median	All	0.886	0.607	.047	4	view →
LUAD	OS	Tertile	All	0.878	1.000	.015	4	view →
LSCC	OS	Quartile	All	1.000	0.928	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LPCAT3–CCRCC (OS)

Open the CCRCC breakdown →